Literature DB >> 16459026

Ductal carcinoma in situ with microinvasion: clinicopathologic study and biopathologic profile.

Antonio Cavaliere1, Massimo Scheibel, Guido Bellezza, Renato Colella, Rino Vitali, Stefania Gori, Cyntia Aristei, Antonio Rulli, Angelo Sidoni.   

Abstract

Data regarding the biologic behavior and surgical management, in particular the axillary lymph node excision, of ductal carcinoma in situ with microinvasion (DCIS-MI) are controversial. Therefore, we decided to study the histopathologic characteristics, the biopathologic profile, as well as the follow-up of a group of patients with DCIS-MI. Thirty-one cases of DCIS-MI, 21 of whom were treated with axillary lymph node dissection, were studied. All cases were classified according to the Van Nuys classification, and the extension of DCIS was quantified. The biopathologic profile (ER, PR, MIB 1, p53, c-erbB-2) as well as the follow-up was also investigated. The results did not reveal any statistically significant differences between the two groups, and there was no statistically significant relationship between the extension of DCIS and the number of microinvasion (MI) foci or maximum MI diameter, or between Van Nuys classification of DCIS and again the number of MI foci or maximum MI diameter. DCIS-MI seems associated with good prognosis. None of the patients had relapses or metastases. Our data seem to suggest that the natural history of DCIS-MI resembles DCIS, and we, therefore, suggest that all the surgically removed area should be examined histologically to avoid missing foci of infiltrating breast cancer larger than 1mm.

Entities:  

Mesh:

Year:  2006        PMID: 16459026     DOI: 10.1016/j.prp.2006.01.001

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  7 in total

1.  Breast ductal Carcinoma in situ associated with microinvasion induces immunological response and predicts ipsilateral invasive recurrence.

Authors:  Xiao-Yang Chen; Aye Aye Thike; Valerie Cui Yun Koh; Nur Diyana Md Nasir; Boon Huat Bay; Puay Hoon Tan
Journal:  Virchows Arch       Date:  2020-11-02       Impact factor: 4.064

2.  Triple negativity and young age as prognostic factors in lymph node-negative invasive ductal carcinoma of 1 cm or less.

Authors:  Ji Hyun Kwon; Yu Jung Kim; Keun-Wook Lee; Do-Youn Oh; So Yeon Park; Jee Hyun Kim; Eui Kyu Chie; Sung-Won Kim; Seock-Ah Im; In-Ah Kim; Tae-You Kim; In Ae Park; Dong-Young Noh; Yung-Jue Bang; Sung Whan Ha
Journal:  BMC Cancer       Date:  2010-10-15       Impact factor: 4.430

3.  The Demographic Features, Clinicopathological Characteristics and Cancer-specific Outcomes for Patients with Microinvasive Breast Cancer: A SEER Database Analysis.

Authors:  Wenna Wang; Wenjie Zhu; Feng Du; Yang Luo; Binghe Xu
Journal:  Sci Rep       Date:  2017-02-06       Impact factor: 4.379

4.  Proposal for Creating a Guideline for Cancer Registration of Microinvasive Tumors of the Breast and Ovary (II).

Authors:  Jin Hee Sohn; Gyungyub Gong; Kyu Rae Kim; Chang Suk Kang; Youn Soo Lee; Jin Man Kim; Woo Hee Jung; Kwang Sun Suh
Journal:  Korean J Pathol       Date:  2012-06-22

5.  Identification of biomarkers in ductal carcinoma in situ of the breast with microinvasion.

Authors:  Yasuhiro Okumura; Yutaka Yamamoto; Zhenhuan Zhang; Tatsuya Toyama; Teru Kawasoe; Mutsuko Ibusuki; Yumi Honda; Ken-ichi Iyama; Hiroko Yamashita; Hirotaka Iwase
Journal:  BMC Cancer       Date:  2008-10-06       Impact factor: 4.430

Review 6.  Tight junctions: a barrier to the initiation and progression of breast cancer?

Authors:  Kieran Brennan; Gozie Offiah; Elaine A McSherry; Ann M Hopkins
Journal:  J Biomed Biotechnol       Date:  2009-11-15

7.  Expression of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and Ki-67 in ductal carcinoma in situ (DCIS) and DCIS with microinvasion.

Authors:  Zhi-Bin Wan; Hong-Yi Gao; Lian Wei; An-Qin Zhang; Jiang-Yu Zhang; Yi Wang; Dong-Dong Wang; Yan Zhang
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.